These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 23178956

  • 1. Response to trastuzumab by HER2 expressing breast tumour xenografts is accompanied by decreased Hexokinase II, glut1 and [18F]-FDG incorporation and changes in 31P-NMR-detectable phosphomonoesters.
    Smith TA, Appleyard MV, Sharp S, Fleming IN, Murray K, Thompson AM.
    Cancer Chemother Pharmacol; 2013 Feb; 71(2):473-80. PubMed ID: 23178956
    [Abstract] [Full Text] [Related]

  • 2. Changes in 2-fluoro-2-deoxy-D-glucose incorporation, hexokinase activity and lactate production by breast cancer cells responding to treatment with the anti-HER-2 antibody trastuzumab.
    Cheyne RW, Trembleau L, McLaughlin A, Smith TA.
    Nucl Med Biol; 2011 Apr; 38(3):339-46. PubMed ID: 21492782
    [Abstract] [Full Text] [Related]

  • 3. Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer.
    Shah C, Miller TW, Wyatt SK, McKinley ET, Olivares MG, Sanchez V, Nolting DD, Buck JR, Zhao P, Ansari MS, Baldwin RM, Gore JC, Schiff R, Arteaga CL, Manning HC.
    Clin Cancer Res; 2009 Jul 15; 15(14):4712-21. PubMed ID: 19584166
    [Abstract] [Full Text] [Related]

  • 4. 18F-FDG small-animal PET/CT differentiates trastuzumab-responsive from unresponsive human breast cancer xenografts in athymic mice.
    McLarty K, Fasih A, Scollard DA, Done SJ, Vines DC, Green DE, Costantini DL, Reilly RM.
    J Nucl Med; 2009 Nov 15; 50(11):1848-56. PubMed ID: 19837760
    [Abstract] [Full Text] [Related]

  • 5. Early changes in [18F]FDG incorporation by breast cancer cells treated with trastuzumab in normoxic conditions: role of the Akt-pathway, glucose transport and HIF-1α.
    Fleming IN, Andriu A, Smith TA.
    Breast Cancer Res Treat; 2014 Apr 15; 144(2):241-8. PubMed ID: 24522376
    [Abstract] [Full Text] [Related]

  • 6. Changes in [18F]Fluoro-2-deoxy-D-glucose incorporation induced by doxorubicin and anti-HER antibodies by breast cancer cells modulated by co-treatment with metformin and its effects on intracellular signalling.
    Cooper AC, Fleming IN, Phyu SM, Smith TA.
    J Cancer Res Clin Oncol; 2015 Sep 15; 141(9):1523-32. PubMed ID: 25579456
    [Abstract] [Full Text] [Related]

  • 7. 2-[18F]-2-deoxy-D-glucose (FDG) uptake in human tumor cells is related to the expression of GLUT-1 and hexokinase II.
    Ong LC, Jin Y, Song IC, Yu S, Zhang K, Chow PK.
    Acta Radiol; 2008 Dec 15; 49(10):1145-53. PubMed ID: 18979289
    [Abstract] [Full Text] [Related]

  • 8. Predicting tumour response to anti-HER1 therapy using medical imaging: a literature review and in vitro study of [18F]-FDG incorporation by breast cancer cells responding to cetuximab.
    Smith TA, Cheyne RW.
    Br J Biomed Sci; 2011 Dec 15; 68(3):158-66. PubMed ID: 21950209
    [Abstract] [Full Text] [Related]

  • 9. Propranolol inhibits glucose metabolism and 18F-FDG uptake of breast cancer through posttranscriptional downregulation of hexokinase-2.
    Kang F, Ma W, Ma X, Shao Y, Yang W, Chen X, Li L, Wang J.
    J Nucl Med; 2014 Mar 15; 55(3):439-45. PubMed ID: 24504055
    [Abstract] [Full Text] [Related]

  • 10. Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET.
    Janjigian YY, Viola-Villegas N, Holland JP, Divilov V, Carlin SD, Gomes-DaGama EM, Chiosis G, Carbonetti G, de Stanchina E, Lewis JS.
    J Nucl Med; 2013 Jun 15; 54(6):936-43. PubMed ID: 23578997
    [Abstract] [Full Text] [Related]

  • 11. Monitoring Src status after dasatinib treatment in HER2+ breast cancer with 89Zr-trastuzumab PET imaging.
    McKnight BN, Viola-Villegas NT.
    Breast Cancer Res; 2018 Oct 25; 20(1):130. PubMed ID: 30359299
    [Abstract] [Full Text] [Related]

  • 12. Tumor uptake and tumor/blood ratios for [89Zr]Zr-DFO-trastuzumab-DM1 on microPET/CT images in NOD/SCID mice with human breast cancer xenografts are directly correlated with HER2 expression and response to trastuzumab-DM1.
    Al-Saden N, Cai Z, Reilly RM.
    Nucl Med Biol; 2018 Dec 25; 67():43-51. PubMed ID: 30390575
    [Abstract] [Full Text] [Related]

  • 13. 18F-FDG and 18F-FLT Uptake Profiles for Breast Cancer Cell Lines Treated with Targeted PI3K/Akt/mTOR Therapies.
    Dockx Y, Vangestel C, De Bruycker S, Van den Wyngaert T, Huizing M, Staelens S, Stroobants S.
    Cancer Biother Radiopharm; 2023 Feb 25; 38(1):51-61. PubMed ID: 36472460
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.
    Gebhart G, Gámez C, Holmes E, Robles J, Garcia C, Cortés M, de Azambuja E, Fauria K, Van Dooren V, Aktan G, Coccia-Portugal MA, Kim SB, Vuylsteke P, Cure H, Eidtmann H, Baselga J, Piccart M, Flamen P, Di Cosimo S.
    J Nucl Med; 2013 Nov 25; 54(11):1862-8. PubMed ID: 24092940
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.